As of Aug 18
| +0.20 / +1.17%|
The 24 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 26.75, with a high estimate of 40.00 and a low estimate of 16.00. The median estimate represents a +54.62% increase from the last price of 17.30.
The current consensus among 30 polled investment analysts is to Hold stock in Teva Pharmaceutical. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.